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The Role of Mesenchymal Stromal 
Cells in the Management of 
Osteoarthritis of the Knee
Charan Thej and Pawan Kumar Gupta
Abstract
Osteoarthritis (OA) is one of the most common chronic, inflammatory, and 
degenerative diseases affecting the synovial joints, the hip, and the knee. OA is 
commonly managed clinically by treating pain with anti-inflammatory medicines 
using nonsteroidal anti-inflammatory drugs (NSAIDS) or analgesics. In severe OA 
patients, invasive knee replacement surgery is the last option. Treatment of OA 
using mesenchymal stromal cells (MSCs) has been widely explored due to their 
anti-inflammatory properties and chondrogenic differentiation potential. In this 
chapter, we comprehensively discuss in detail the in vitro OA potency development, 
OA preclinical studies, and clinical trials conducted using MSCs.
Keywords: osteoarthritis, pooled human bone marrow-derived mesenchymal 
stromal cells, potency assay, preclinical studies, clinical studies
1. Introduction
Common factors linked to osteoarthritis (OA) occurrence are increasing age 
(>55 years) and obesity [1]. The gender also seems to play a major role, where 
the majority of OA patients are women and higher prevalence has been liked to 
menopause. Radiological evidence suggests that about 70% of women above the age 
of 65 years are affected by OA [2, 3]. Other factors such as genetic predisposition, 
extrinsic environmental factors, nutrition, and lack of exercise are reasons for the 
increased prevalence of OA. It has been reported by the World Health Organization 
(WHO) that 10–15% of the populations aged >60 years exhibit a certain degree of 
OA [4]. It has been reported by the National Health Portal of India that 22–39% 
of the Indian population are affected by OA. As reported by the United Nations 
Organization (UNO), 130 million people will be affected by OA with over 40 mil-
lion people with severe disability due to disease progression [3].
The etiology of OA is believed to be multifactorial. Some of the main reasons 
include the biomechanical disease progression due to the narrowing of space in the 
joints, bone hypertrophy, and formation of new osteophytes in the articular margins 
causing stiffness and pain in the joints. In addition, an imbalance in the synthesis and 
release of cytokines by chondrocytes in the disease state could be the main reason for 
the continual inflammatory state in the joint. During the initial stages of OA, catabolic 
interleukins (IL) such as IL-1α and IL-1β and tumor necrosis factor α (TNFα) increase 
inflammation affecting cartilage metabolism and homeostasis. TNFα is a proinflam-
matory cytokine implicated in the degradation of matrix proteins synthesized by 
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chondrocytes and synoviocytes [5]. Further, increase in the levels of interferon γ 
(IFNγ) in the joint worsens the inflammatory state and structure of the joint leading to 
degradation of proteoglycans such as sulfated glycosaminoglycans (sGAG) [5, 6].
2. Current treatment options for osteoarthritis
Currently, pain in OA is pharmacologically managed using nonsteroidal anti-
inflammatory drugs (NSAIDS), opioids, and analgesics. Corticosteroid injections 
have also been used for relieving severe pain in OA patients. Recent attempts have 
been made to use TNFα blockers as recent studies have proven the significant role 
of TNFα in contribution to the pathogenesis of OA [7]. Research by several groups 
has implicated the role of nerve growth factor (NGF) and its binding to tropomyo-
sin receptor kinase A (trk A) which leads to downstream signaling and activation 
of peripheral and central pain molecules causing severe pain. The therapeutic 
efficiency of anti-NGF antibodies to block NGF or its antagonists has been studied 
by several groups for relieving pain. The pain-relieving effects of anti-NGF anti-
bodies fasinumab and fulranumab manufactured by Regeneron Pharmaceuticals 
and Janssen Pharmaceutica, respectively, have been evaluated in phase III clinical 
trials [8]. In addition to pain relief, efforts have been made to halt further cartilage 
damage using slow-acting symptomatic drugs such as chondroitin sulfate and 
glucosamine sulfate. Orally administered chondroitin and glucosamine have shown 
to relieve joint pain equivalently compared to NSAIDs. These molecules, intact or 
broken, could be absorbed into the matrix of the joint and prevent cartilage degen-
eration. Although glucosamine and chondroitin sulfate have been clinically proven 
to be safe, their therapeutic efficacy in protecting the cartilage matrix was found 
to the variable [9]. In grade 4 OA (Kellgren and Lawrence classifications), patients 
are advised to opt for total knee replacement surgery [10]. Alternatively, autologous 
chondrocyte implantation (ACI) has been suggested and reported to be successful. 
In the ACI method, the chondrocytes from patients are taken, culture-expanded 
in vitro, and then implanted back into the knees of patients. This procedure is 
invasive and has a lesser success rate than total knee replacement surgeries [11].
Apart from ACI, the efficacy of autologous platelet-rich plasma (PRP) in provid-
ing pain relief and promoting cartilage regeneration has been recently investigated by 
several groups [12]. The PRP is rich in platelets that secrete several growth factors and 
cytokines such as platelet-derived growth factor (PDGF), hepatocyte growth fac-
tor (HGF), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor 
(VEGF), and prostaglandin E2 (PGE-2) [13]. Several research groups have reported 
that intra-articular injections of PRP primarily reduced inflammation mediated by 
PGE-2, HGF, and IGF-1. IGF-1 synthesized and secreted by platelets is shown to 
prevent leukocyte infiltration into the joint space, thereby reducing the levels of IL-1β 
and TNFα in the synovial fluid [13]. Overall intra-articular injection of PRP has been 
shown to maintain joint homeostasis. However, clinical trial data suggest that the 
effect of PRP seems to last for only 3 weeks and thereafter reduces. The symptoms 
of OA were seen to relapse after a period of 1 year. Although promising results were 
observed using PRP in the hydrogel, chitosan, or hyaluronic acid (HA) scaffolds [14], 
efficacy is yet to be shown in elaborate randomized clinical trials (RCTs).
3. Mesenchymal stromal cells
The history of mesenchymal stromal/stem cells (MSCs) dates back to 1960 when 
seminal studies conducted by Friedenstein showed the isolation of MSCs from bone 
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marrow (BM) which were capable of forming ectopic bone in vivo. This was found to 
be a non-hematopoietic fibroblast-like, colony-forming cell which primarily sup-
ported hematopoietic stem cells in the perivascular niche [15]. Owen and Friedenstein 
discovered that these cells were capable of differentiating into the osteogenic lineage 
[16]. Subsequently, the multipotent plasticity of that bone marrow MSCs (BMMSCs) 
was identified and shown that they were capable of differentiating into osteocytes, 
chondrocytes, and adipocytes in vitro [17]. In addition to the abovementioned 
three lineages, Caplan and colleagues demonstrated that these cells were capable of 
differentiating into cells of the muscle, tendons/ligaments, and connective tissue 
after which he coined the term “mesenchymal stem cells” [18]. Bianco and Gehron 
Robey deduced that cbfa1 gene was the master regulator for directing the osteogenic 
fate of MSCs. Because of the ability of MSCs to form osteocytes, they named them 
skeletal stem cells [19]. In 2006, the International Society for Cellular Therapy 
(ISCT) proposed the name multipotent mesenchymal stromal cells and defined that 
MSCs must adhere to the criteria of being plastic adherent; express surface markers 
CD105, CD73, and CD90; lack the expression of hematopoietic markers CD45, CD34, 
CD14 or CD11b, CD79α or CD19, and HLA-DR; and differentiate into osteoblasts, 
chondrocytes, and adipocytes under suitable conditions in vitro [20]. In addition to 
their differentiation capacity, MSCs have been shown to elicit immunosuppressive and 
immunomodulatory effects on T lymphocytes, B cells, dendritic cells (DC), and natu-
ral killer (NK) cells either by cell-cell interactions or by secretion of anti-inflammatory 
molecules such as indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE-2),  
interleukin-4 (IL-4), interleukin-10 (IL-10), and transforming growth factor β 
(TGFβ) making them ideal cell types for treatment of diseases [21–23]. Because of 
their ability to differentiate into chondrocytes in vitro and with their anti-inflamma-
tory and immunomodulatory functions, they were believed to be candidate cell type 
to treat diseases such as OA. MSCs have been isolated from over 18 different tissue 
sources. The most commonly used tissue sources for isolating MSCs apart from bone 
marrow are the adipose tissue, umbilical cord, placenta, and dental pulp. However, 
autologous or allogeneic BMMSCs are currently the most widely used cell type in clini-
cal trials for various disease indications. They are considered the “gold standard” MSC 
type because of their extensive characterization that took place for over 5 decades.
4.  Possible mechanism of action (MoA) of BMMSCs for treatment of 
osteoarthritis
The pathophysiology of OA is characterized by degradation of hyaline cartilage 
causing narrowing of joint space leading to subchondral sclerosis, subchondral 
cysts, hypertrophic chondrocytes, and formation of osteophytes. The fric-
tion caused by the rubbing of joints results in chronic pain in OA patients [24]. 
Degeneration of cartilage extracellular matrix (ECM) may be caused due to the 
increase in the levels of proteolytic enzymes such as matrix metalloproteases 
(MMPs) and aggrecanases mediated by IL-1β and TNFα [25]. BMMSCs express a 
wide range of properties that are anticipated to be beneficial for treating genetic, 
mechanical, and age-related degeneration in diseases such as OA. In our previous 
publication, we have in detail attempted to deduce the possible mechanism of action 
(MoA) of allogeneic pooled BMMSC population [25]. Briefly, BMMSCs are known 
to be immunomodulatory in nature, primarily because of their potential to signifi-
cantly suppress the proliferation of inflammatory T cells, monocytes, and dendritic 
cells either by direct cell-to-cell contact. In addition, they secrete a wide range of 
anti-inflammatory molecules such as PGE-2, IDO, IL1Ra, and IL-10 [26, 27].  
BMMSCs influence the local osteoarthritic microenvironment by stimulating 
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resident chondrogenic progenitor cells and promote their differentiation into 
mature chondrocytes mediated by secretion of bone morphogenetic proteins 
(BMPs) and TGFβ1 [28]. BMMSCs are known to differentiate into chondrocytes 
in vitro using differentiation cues such as BMP-7 and TGFβ1. A similar mechanism 
could be involved in the differentiation of BMMSCs in vivo. With the increase 
in the levels of BMP-7 and TGFβ1 in the local joint milieu, mediated by a change 
in expression of master regulatory genes such as Sox9, HoxA, HoxD, and Gli3, 
BMMSCs could differentiate into chondrogenic progenitor cells (CPCs) in vivo. The 
CPCs further differentiate into chondroblasts characterized by definitive upregula-
tion of collagen types II B, IX, and XI. Subsequently, the CPCs differentiate into 
mature chondrocytes regulated by balanced expression of collagen X (Col X) and 
synthesize the secretion of collagen II which is made of sGAG building blocks which 
maintain the structural integrity of hyaline cartilage [25]. Very high expression 
of collagen X has been linked to hypertrophy of chondrocytes and formation of 
fibrous cartilage, and thus a regulated expression of Col X would likely result in 
deposition of hyaline cartilage [29]. From the above-described multimodal MoA, 
it is clear that BMMSCs are an ideal cell population which could contribute signifi-
cantly for an effective treatment of OA.
5.  Advantages of using a pooled human BMMSC (phBMMSC, 
Stempeucel®) product for treating osteoarthritis
In the current therapeutic scenario, the common practice is to screen several indi-
vidual donors, isolate MSCs, and characterize them based on their key characteristics 
such as their surface marker expression, tri-lineage differentiation potential, and 
immunomodulatory and paracrine properties [30–32]. It is inevitable that a product 
that is manufactured using a master cell bank (MCB) made from a single donor will 
result in exhaustion. Successively, a product that is made using another single donor 
MSC bank, although presumably similar in basic characteristics qualifying the iden-
tity and safety criteria, may not have the same functional attributes which may lead to 
varied therapeutic outcomes. Eminent scientific groups have demonstrated donor-to-
donor variability in properties of MSCs such as their clonogenicity, growth kinetics, 
and differentiation potential [33]. A comparative analysis of five different BMMSC 
populations showed significant variation in the proteomic profile of these cells. Only 
13% similarity in the proteomic profile which included transcriptional and transla-
tional regulators, kinases, receptor proteins, and cytokines between the five BMMSC 
populations was found. A maximum of 72% similarity in the proteome was observed 
between two of the five analyzed cell populations [34]. Disparities in clinical trial 
outcomes have been reported where BMMSCs derived from single donors have been 
used. A steroid-refractory acute graft-versus-host disease (SR-aGvHD) clinical trial 
conducted in both children (n = 25) and adults (n = 30) using BMMSC products 
derived from 92 HLA-matched and HLA-mismatched donors resulted in only 50% 
overall durable complete response, while the remaining patients did not respond or 
partially responded to the treatment [35]. Similar variations with limited response 
rates were observed in a phase III GvHD trial conducted by Osiris Therapeutics 
using Prochymal® with only 35% complete response rate compared to 30% in the 
placebo arm [36]. It has been suggested that improper selection of a BM donor and 
making a single donor-derived cell product could lead to substantial variations in 
therapeutic outcomes [37]. In order to challenge this issue, some scientific groups 
have suggested pooling of BMMSCs from two or more donors in order to compensate 
for the variation and balance the properties between different donor cell populations. 
Samuelsson et al. showed that a two- or three-donor pooled BMMSC product could 
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optimize the immunosuppressive properties of these cells in vitro [38]. Later, Kuçi 
et al. showed substantial variability in the immunosuppressive properties of indi-
vidual donor-derived BMMSCs (n = 8). On the contrary, a mesenchymal end product 
(MEP) made by pooling BMMNCs from eight donors resulted in a cell population that 
consistently suppressed an MLR in vitro [39]. Subsequently, they went on to conduct 
a multicentric SR-aGvHD clinical trial in 51 children and 18 adults using MEP/MSC 
Frankfurt am Main (MSC-FFM, Obnitix®) cells and observed 83% overall response 
(complete response, 32%; partial response, 51%) [40]. At Stempeutics Research Pvt. 
Ltd., we were the first group to develop an allogeneic pooled human BMMSC product 
called Stempeucel® using an established, robust pooling protocol and a two-tier 
manufacturing and banking system as previously described [41, 42]. Recently, we 
have published our comprehensive studies including in vitro chondrogenic proper-
ties and preclinical and clinical findings establishing the efficacy and safety of using 
Stempeucel® for the treatment of OA of the knee joint [43]. In this study, we found 
that several manufactured batches of Stempeucel®, when differentiated into the 
chondrocyte lineage, downregulated the expression of the gene Sox9 and upregulated 
the expression of collagen type 2A (Col2A) gene confirming their differentiation into 
the chondrogenic lineage. The same Stempeucel® batches synthesized substantial 
levels of sGAG (30 ± 1.8 μg/μg GAG/DNA) which were estimated using a dimethyl-
methylene blue-based biochemical assay kit (Figure 1). These properties indicate that 
Stempeucel® could be a potential treatment option for treating OA.
6.  Development of a potency assay for Stempeucel® intended to treat 
osteoarthritis
The US Food and Drug Administration (USFDA) describes potency assays as “The 
specific ability or capacity of the product, as indicated by appropriate laboratory tests 
or by adequately controlled clinical data obtained through the administration of the 
Figure 1. 
Chondrogenic potency assessment using quantification of sGAG in 16 batches of Stempeucel® cryopreserved in 
PlasmaLyte A-based cryopreservation solution and 4 batches of Stempeucel® cryopreserved in CS 5.
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product in the manner intended, to effect a given result” (US-FDA, 21 CFR 600). 
For any cell therapy product (CTP) intended to be used for a particular indication, a 
specific, quantifiable, potency test or array must be developed. The development of 
a potency assay must begin with in vitro and preclinical studies based on the MoA of 
the CTP. The confirmation of the assay or the identified marker must be evaluated in 
every large-scale manufactured batch of the CTP during the progress of the phase I 
and phase II clinical studies. A quantifiable range for the potency test must be defined 
and implemented during the course of phase III clinical trial [44]. In order to predict 
the efficacy of a CTP, either in vitro biochemical assays or biological assays or in vivo 
biological assessment could be implemented. For example, a company called TiGenix 
(Leuven, Belgium) has developed and adopted an assay matrix where an ex vivo poly-
merase chain reaction (PCR) array for autologous chondrocytes (ChondroCelect) is 
performed and ectopic cartilage formation is correlated to the histology sections of an 
orthotopic goat model where ChondroCelect is implanted [45, 46]. Jeong et al. have 
demonstrated that thrombospondin-2 (TSP-2) could be an effective marker to predict 
the chondrogenic efficiency of umbilical cord-derived MSCs (UC-MSCs). They 
demonstrated that UC-MSCs, through the TSP-2 secretion, can promote chondro-
genesis via PKCa, ERK, P38/MAPK, and Notch signaling pathways [47]. Recently, 
another group estimated the levels of TSP-2 to evaluate the chondrogenic potency of a 
UC-MSC product (Cellistem®OA, Cells for Cells, Brazil) intended to be used in phase 
I/phase II RCT for knee OA [48]. Other scientific groups have shown that autologous 
culture-expanded chondrocytes could be embedded in collagen-1 and injected 
subcutaneously in nude mice to predict the potency of several bioactive molecules 
in promoting chondrogenesis [49]. For the first time, we have developed a chondro-
genic potency assay for an allogeneic pooled bone marrow-derived MSC product 
(phBMMSCs, Stempeucel®). Preliminarily, we culture-expanded and differentiated 
several Stempeucel® batches into the chondrogenic lineage using commercially 
available differentiation assay kits (Thermo Fisher Scientific, USA). To confirm the 
differentiation, we evaluated the Col2A mRNA expression in differentiated cells and 
compared them with the undifferentiated control cells. After observing a significant 
increase in the Col2A expression of differentiated cells, we enzymatically digested 
both the differentiated and undifferentiated cells to quantify the levels of sGAG syn-
thesized by these cells using a 1,9-dimethylmethylene blue (DMMB)-based assay kit 
(Blyscan, Biocolor, UK). We further normalized the levels of sGAG with the amount 
of DNA from the same number of cells. We evaluated the sGAG levels in 20 batches of 
Stempeucel® of which 16 batches were cryopreserved in our older formulation (10% 
dimethyl sulfoxide (DMSO), 5% human serum albumin (HSA) and PlasmaLyte A) 
and also four batches of Stempeucel® cryopreserved in a new cGMP grade CryoStor 
5 solution (CS5, BioLife Solutions). We observed a significant and consistent increase 
in the levels of sGAG in the differentiated cells compared to the undifferentiated cells 
(undifferentiated, 11.9 ± 4.6 GAG/DNA (μg/μg); differentiated, 31 ± 8.6 GAG/DNA 
(μg/μg; P < 0.0001; n = 20)) (Figure 1). Based on our results, we propose that the 
sGAG assay is a simple, quantifiable, and robust potency assay which could also be a 
part of a bigger potency assay matrix to predict the chondrogenic potency of thera-
peutic cells intended to treat cartilage defects.
7. Preclinical efficacy studies in OA
Many studies have demonstrated that MSCs are nontoxic and non-tumorigenic 
when tested in various animal models [50, 51]. Prior to evaluating the efficacy of 
Stempeucel® in an appropriate preclinical model of OA, we had earlier evalu-
ated the preclinical safety and toxicity of Stempeucel® in rodent and non-rodent 
7The Role of Mesenchymal Stromal Cells in the Management of Osteoarthritis of the Knee
DOI: http://dx.doi.org/10.5772/intechopen.86016
models. In the same study, we evaluated the feasibility of multiple routes of cell 
injection. Tumorigenic analysis in severe combined immunodeficient (SCID) mice 
showed that Stempeucel® is non-tumorigenic. In addition, the biodistribution 
kinetics of CM-DiI labeled Stempeucel® in the systemic circulation and also in 
muscle tissue were studied in both rats and mice [51].
It is important to demonstrate the efficacy of any cell therapy product in an ani-
mal model of disease before administrating the product in humans with the same 
disease. It is imperative to determine the suitability of using animal stem cells in 
animals or human stem cells in immunocompromised/immunocompetent animals. 
A common regulatory requirement is to have animal data for the same test product 
that is intended to be tested in humans. In our recently published work, we evalu-
ated the efficacy of Stempeucel® in a monosodium iodoacetate (MIA)-induced 
Author/
year
Animal OA model Cell type and 
dose
Vehicle Study 
duration 
time 
points
Reference
Murphy 
et al. (2003)
Goat ACLT-
meniscectomy
10 × 106 
Autologous (goat) 
BMMSC + HA
HA 12 and 
26 weeks
[65]
Frisbie et al. 
(2009)
Horse Arthroscopic 
surgery
10.5 × 106 
Autologous 
(horse) BMMSC
Saline 10 weeks [61]
Sato et al. 
(2012)
Pig Spontaneous 7 × 106 Xenogeneic 
(human) BMMSC
HA/PBS 1, 3, and 
5 weeks
[66]
Song et al. 
(2014)
Sheep ACLT-
meniscectomy
10 × 106 
Autologous 
(sheep) BMMSC
PBS 8 weeks [63]
Delling 
et al. (2015)
Sheep Bilateral 
meniscectomy
20 × 106 
Autologous 
(sheep) BMMSC
PBS 0, 1, 4, 
8, and 
12 weeks
[64]
Singh et al. 
(2014)
Rabbit ACLT 1 × 106 Autologous 
(rabbit) BMMSC
Culture 
medium
4 and 
6 weeks
[55]
Chiang 
et al. (2016)
Rabbit ACLT 1 × 106 Allogeneic 
(rabbit) BMMSC
HA 6 and 
12 weeks
[56]
Diekman 
et al. (2013)
Mouse Closed tibial 
plateau 
fracture
1 × 105 Allogeneic 
(mice) BMMSC
Saline/mouse 
albumin
8 weeks [52]
Suhaeb 
et al. (2012)
Rat MIA injection 3.5 × 106 
Allogeneic (rat) 
BMMSC
HA 3 and 
9 weeks
[67]
Kim et al. 
(2014)
Rat ACLT-
meniscectomy
1 × 106 Allogeneic 
(rat) BMMSC
Culture 
medium
3 and 
6 weeks
[53]
Yang et al. 
(2015)
Rat ACLT-
meniscectomy
0.5 × 106 
Autologous (rat) 
BMMSC
PBS 3 weeks [54]
Gupta et al. 
(2016)
Rat MIA injection 0.6 × 106 
or 1.3 × 106 
Xenogeneic 
(human) pooled 
BMMSC
PlasmaLyte A 4, 8, and 
12 weeks
[43]
Table 1. 
OA preclinical studies using BMMSCs.
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OA model in Wistar rats. We demonstrated the dose-dependent efficacy of two 
Stempeucel® doses of 0.65 × 106 (25 × 106 human equivalent dose, HED) and 
1.3 × 106 (50 × 106 HED) followed by an injection of hyaluronic acid (HA). A 
significant dose-dependent reduction in pain scores was observed in both low and 
high Stempeucel® doses compared to the HA alone and disease control group. 
Histological evaluation of joint tissue sections in all study groups showed significant 
improvement in proteoglycan staining in both low and high Stempeucel® admin-
istered groups indicating significant regeneration of the cartilage in both groups 
compared to the HA alone and disease control groups [43].
Similar to the animal model we used, other scientific groups have created articu-
lar cartilage defects in small animals, such as mice [52], rats [43, 53, 54], and rabbits 
[55, 56]. Smaller animal models are cost-effective and easy to house, and rodents are 
available in a variety of genetically modified strains with minimal biological vari-
ability [57, 58]. However, the small joint size, thin cartilage, altered biomechanics, 
and increased spontaneous intrinsic healing hamper the study of the regenerative 
capacity of stem cells and these mechanisms of healing which cannot be fully 
extrapolated to human cartilage repair [59, 60]. Rodents have mainly been used to 
assess the chondrogenesis of cell-based therapies by subcutaneous, intramuscular, 
and intra-articular implantations of cells [60]. Of all small animals, the rabbit 
model is the most utilized model in cartilage regeneration studies because of the 
slightly larger knee joint size than rodents [55, 56]. Despite their limited translational 
capacity, small animals can be very useful as a proof-of-principle study and to assess 
therapy safety before moving on to preclinical studies using larger animals [60].
Large animal models play a more substantial role in translational research 
because of a larger joint size and thicker cartilage; however, their preclinical use is 
often hindered by high costs and difficulties in animal handling. A variety of large 
animal models have been used to investigate cartilage repair strategies, including 
horses [61], dogs [62], sheep [63, 64], goats [65], and pigs [66], each with their own 
strengths and limitations. We have listed some relevant published studies which 
have used autologous, allogeneic, or xenogeneic BMMSCs to treat OA induced by 
various methods (Table 1).
Based on the positive efficacy outcomes of our preclinical study, subsequently, 
we demonstrated the safety and optimal dose for efficacy in a phBMMSC product, 
Stempeucel®, in a randomized, double-blind, placebo-controlled dose-finding 
phase II clinical trial in Indian patients [43].
8. Clinical trials in osteoarthritis of the knee joint
8.1 Safety of mesenchymal stromal cells in clinical trials
Lalu MM et al. conducted a systematic review of clinical trials that examined the 
use of MSCs to evaluate their safety [68]. A total of 36 studies having 1012 partici-
pants with different clinical conditions was evaluated. Eight studies were random-
ized control trials (RCTs) and enrolled 321 participants. Only prospective clinical 
trials that used the intravenous or intra-arterial route of administration in different 
age groups were analyzed. Meta-analysis did not detect an association with MSC 
administration and acute infusional toxicity, organ system complications, infection, 
and death. There was a significant association between MSCs and transient fever 
at or shortly after MSC administration which was not associated with long-term 
sequelae. Most importantly, the meta-analysis showed no serious adverse event due 
to the administration of MSCs and specifically found no association between MSCs 
and tumor formation. In another study, Peeters et al. [69] did a systemic review of 
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the safety of intra-articular administration of culture-expanded stem cells. A total 
of 844 procedures (mean follow-up of 21 months) was analyzed. Four SAEs were 
reported—one infection following bone marrow aspiration (BMA) that resolved 
with antibiotics, one pulmonary embolism after 2 weeks of BMA, and two adverse 
events not related to the therapy. Other adverse events documented were increased 
pain/swelling and dehydration after BMA. In another review, a recent analysis of 
adverse events (AEs) in 2372 orthopedic patients treated with autologous stem 
cell therapies and followed up for 2.2 years has been published [70]. The common 
AEs reported included post-procedure pain and pain due to progressive degenera-
tive joint disease in under 4% of the population. Hence, we can conclude that the 
systemic administration of MSC including intra-articular administration is safe.
8.2  Efficacy of stem cells including mesenchymal stromal cells in clinical trials 
of osteoarthritis of the knee joint
Several clinical trials have been conducted using bone marrow mononuclear 
cells, adipose tissue-derived stromal vascular fraction (AD-SVF), adipose tissue-
derived mesenchymal stromal cells (AD-MSCs), or bone marrow-derived mesen-
chymal stromal cells (BMMSCs) in OA of the knee joint. The list of the published 
clinical trials in chronological order is given in Table 2. Administration of the cells 
has been fairly standardized, with the cells being administered either directly intra-
articularly or under ultrasound guidance. Few trials have been conducted using the 
arthroscopic method of administration with direct implantation of the cells alone or 
with a scaffold at the site of cartilage injury.
The first clinical study has been published way back in 2002 by Wakitani et al. 
[71]. In this study of 12 patients who underwent high tibial osteotomy, BMMSCs at 
a dose of 13 million cells were embedded in collagen gel and transplanted into the 
cartilage defect and covered with autologous periosteum. The clinical improvement 
was not significantly different from the control group, but the arthroscopic and his-
tological evidence was better in the transplanted group than the control arm. Since 
then many studies have been published, but still many contentious issues regarding 
cell therapy in OA are being discussed. We will try to discuss a few burning issues in 
this chapter:
a. Level of evidence regarding the use of MSC therapy in OA: Jevotovsky 
et al. [106] did a systemic review of 61 studies to look at the study evidence 
level, MSC protocol, treatment results, and AEs. The levels of evidence were 
defined by Marx et al. stating the level of evidence as level 1, randomized 
controlled trial; level II, prospective cohort study or observational study with 
dramatic effects; level III, retrospective cohort study or case–control study; 
level IV, case series; and level V, mechanism-based reasoning [107]. These 
levels of evidence help physicians to come to clinical decisions. In this review, 
a total of 2390 patients in 61 studies was identified. Most of the studies used 
adipose-derived stem cells (ADSCs) (n = 29) or bone marrow-derived stem 
cells (BMSCs) (n = 30). The majority of the studies (57%) were level IV evi-
dence which consists of therapeutic case series without comparative groups. 
Only five and nine studies were level I and level II evidence, respectively, in 
a total of 288 patients. Additionally, 11% were level III retrospective cohort 
studies, and 8% were level V single-patient case reports. The published data 
highlights the need for more level I and level II evidence to evaluate the 
role of MSC treatment in OA patients. However, the majority of the studies 
have reported positive results and an association between MSC therapy and 
symptomatic and radiologic improvement in these patients.
U
p
d
ate on
 M
esen
chym
a
l an
d
 In
d
u
ced
 P
lurip
oten
t Stem
 C
ells
10
Author/
year
Sample 
size
Study design Grade of OA Cell type and dose Control group Outcome measures Outcomes Follow-up 
period
Reference
Wakitani 
(2002)
24 A single-arm 
control study
Stage I to stage 
II Ahlback 
changes
Auto BMMSC, 13 × 106 
cells embedded in 
soluble collagen (n = 12)
High tibial 
osteotomy 
(n = 12)
Hospital for Special 
Surgery knee rating 
scale, arthroscopy 
and histology
No significant difference in 
clinical evaluations between 
the two groups, arthroscopy 
and histology showed partially 
hyaline cartilage-like tissue
16 months [71]
Centeno 
et al. 
(2008)
1 Case study — Auto BMMSC, 2.4 × 106 
cells + 1 ml NC + 1 ml 
PRP
Nil VAS, ROM, and 
MRI
Decreased VAS pain scores; 
increased the range of motion; 
MRI, statistically significant 
cartilage and meniscus growth
6 months [72]
Haleem 
et al. 
(2010)
5 Case series Outerbridge 
grade III or 
grade IV
Auto BMMSC + PR-FG, 
15 × 106 cells
Nil Lysholm and 
RHSSK scores and 
X-rays and MRI
Lysholm and RHSSK scores 
showed statistically significant 
improvement, MRI of three 
patients revealed complete 
defect fill
12 months [73]
Nejadnik 
et al. 
(2010)
72 Cohort study Lesion grade 3 
or grade 4
Auto BMMSC n = 12 each in 
BMMSC and 
chondrocyte 
group
ICRS, SF-36, IKDC, 
Lysholm knee scale 
and Tegner activity 
level scale
SF-36 showed physical role 
functioning improvement 
in the BMMSC group, no 
difference in other outcome 
measures
24 months [74]
Davatchi 
et al. 
(2011)
4 Single-arm 
study
Moderate to 
severe OA
Auto BMMSC, 8–9 × 106 
cells
Nil VAS pain score, 
time to walk and 
number of stairs to 
climb to produce 
pain, the resting 
time to induce the 
gelling pain, ROM 
and patellae crepitus
Walking time for the pain to 
appear improved for three 
patient, VAS pain score and 
number of stairs to climb 
improved for all patients, 
improvement in crepitus
6 months [75]
Saw et al. 
(2011)
5 Single-arm 
study
ICRS grade 3 
or grade 4
Auto PBPC (8 ml) + HA/
weekly injection × 5
Nil Arthroscopy and 
histology
Arthroscopy showed articular 
cartilage regeneration and 
histologically showed hyaline 
cartilage
26 months [76]
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Koh et al. 
(2012)
25 Case–control 
study
KL grade 3 or 
grade 4
Arthroscopic 
debridement + Auto 
AD-MSC, 1.89 × 106 cells 
+ PRP
Arthroscopic 
debridement 
+ PRP
Lysholm score, 
Tegner activity 
scale, and VAS 
scores
The clinical scores 
preoperatively were 
significantly poorer than those 
of the control group but at 
the last follow-up visit were 
similar and not significantly 
different between the two 
groups
18 months [77]
Orozco 
et al. 
(2013)
12 Case series KL grade 2 to 
grade 4
Auto BMMSC, 40 × 106 
cells
Nil VAS score, 
Lequesne indexes, 
WOMAC scores, 
MRI T2 mapping
All clinical scores decreased 
significantly, MRI T2 mapping 
showed improvement of 
cartilage quality
12 months [78]
Koh et al. 
(2013)
18 Case series KL grade 3 or 
grade 4
Auto AD-MSC, 1.18 × 106 
cells + PRP
Nil WOMAC score, 
Lysholm score, 
Tegner activity 
scale, and VAS 
scores, MRI 
(WORMS score)
WOMAC, Lysholm, Tegner, 
and VAS scores improved 
significantly, WORMS score in 
MRI improved significantly
26 months [79]
Van 
Pham 
et al. 
(2014)
21 Case series KL grade 2 or 
grade 3
Auto SVF Nil VAS, Lysholm score, 
and MRI
VAS scores improved, Lysholm 
scores increased, MRI showed 
increased cartilage thickness
8.5 months [80]
Koh et al. 
(2014)
37 knees 
(35 
patients)
Case series KL grade 1 or 
grade 2
Auto AD-MSC, 3.8 × 106 
cells
Nil IKDC score, Tegner 
activity scale, and 
cartilage repair 
assessed using ICRS 
grading
IKDC and Tegner activity scale 
scores significantly improved, 
ICRS grades showed 2 of the 
37 lesions (5%) were grade I 
(normal) and 7 (19%) were 
grade II (near normal)
26.5 months [81]
Koh et al. 
(2015)
30 Case series KL grade 2 or 
grade 3
Auto SVF + PRP, 42 × 106 
cells
Nil Lysholm score, 
KOOS, VAS score, 
arthroscopic 
evaluation (n = 16)
Significant improvement in 
all clinical outcomes, 87.5% of 
patients (14/16) improved or 
maintained cartilage status
24 months [82]
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Munar 
et al. 
(2015)
50 Case series KL grade 2 to 
grade 4
Auto BMMSC, 40 × 106 
cells
Nil VAS, Lequesne and 
WOMAC indices, 
MRI (T2 mapping)
All clinical scores improved, 
T2 mapping, PCI decreased 
significantly
12 months [83]
Davatchi 
et al. 
(2016)
4 Case series Moderate to 
severe OA
Auto BMMSC, 8–9 × 106 
cells
Nil VAS pain score, 
time to walk and 
number of stairs to 
climb to produce 
pain, the resting 
time to induce the 
gelling pain, ROM 
and patellae crepitus
All parameters still better than 
baseline at 5 years follow-up 
for three patients
60 months [84]
Soler 
et al. 
(2016)
15 Single-arm, 
open-label 
phase I/phase 
II trial
KL grade 2 or 
grade 3
Auto BMMSC, 41 × 106 
cells
Nil VAS score, 
questionnaire, 
QOL SF-36 
questionnaire, 
Lequesne functional 
index and WOMAC 
score, MRI (T2 
mapping)
The clinical scores improved, 
SF-36 showed improvement 
of parameters, T2 mapping 
showed signs of cartilage 
regeneration
12 months [85]
Sampson 
et al. 
(2016)
125 Retrospective 
case series
KL grade 3 or 
grade 4
Auto BMC + PRP 
(8 weeks apart)
Nil VAS score, patient 
satisfaction scale
VAS score and patient 
satisfaction score improved in 
all patients
4.8 months [86]
Fodor 
and 
Paulseth 
(2016)
6 patients 
(8 knees)
Case series KL grade 1 to 
grade 3
Auto SVF, 14.1 × 106 cells Nil VAS score, WOMAC 
score, ROM, TUG 
test, and MRI
VAS and WOMAC scores 
significantly improved, 
ROM and TUG improved, 
MRI showed no detectable 
structural differences
12 months [87]
Kim et al. 
(2016)
20 
patients 
(24 knees)
Case series KL grade 1 or 
grade 2
Auto AD-MSC, 4.4 × 106 
cells
Nil IKDC score, Tegner 
activity scale, 
MRI MOAKS and 
MOCART score
Clinical outcomes significantly 
improved, MOAKS and 
MOCART score significantly 
improved
24 months [88]
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Pak et al. 
(2016)
3 Case reports KL grade 3 Auto AD-SVF + HA + PRP, 
PRP repeated weekly × 3
Nil FRI, ROM and VAS 
score, MRI
All clinical scores improved in 
three patients, MRI showed 
cartilage-like tissue regeneration
4.5 months [89]
Pers et al. 
(2016)
18 Open-label, 
phase I study
KL grade 3 or 
grade 4
Auto AD-MSC, low 
(2 × 106), medium 
(10 × 106), and high dose 
(50x106), 6 patients each
Nil Safety, WOMAC, VAS, 
PGA, SAS and KOOS 
index, MRI, dGEMRIC 
in 6 patients
Safety established, low dose 
most effective, and all parameters 
improved as compared to baseline, 
dGEMRIC improved in three patients
6 months [90]
Koh et al. 
(2016)
80 RCT ICRS grade 3 or 
grade 4
Auto AD-MSC + fibrin glue 
+ microfracture, 5 × 106 
cells (group 1)
n = 40 (group 2) 
(microfracture)
Lysholm score, 
KOOS, VAS score, 
MRI, cartilage repair 
tissue scoring system, 
arthroscopy and 
histology
MRI, better signal intensity for 
repair tissue in group 1 (80%) as 
compared to 72.5% in group 2; 
KOOS pain and symptom 
subscores, significantly greater 
for group 1; arthroscopy and 
histology, no significant difference
24 months [91]
Gupta 
et al. 
(2016)
60 Double-blind, 
phase II, RCT
KL grade 2 or 
grade 3
Allo BMMSC + HA, four 
doses (25, 50, 75, 150 × 106 
cells)
n = 20 (placebo 
+ HA)
Safety, VAS, ICOAP, 
WOMAC, MRI, 
WORMS score
Safety established; AE were 
predominant in the higher-dose 
groups; VAS, ICOAP, and WOMAC 
scores best in the lowest dose; MRI, 
no significant difference
24 months [43]
Lamo-
Espinosa 
et al. 
(2016)
30 Phase I/phase 
II, RCT
KL grade 2 to 
grade 4
Auto BMMSC + HA, two 
doses (10 and 100 × 106 
cells)
n = 10, (HA) Safety, VAS score, 
WOMAC, MRI, 
WORMS
Safety established. VAS, 
WOMAC, and WORMS scores 
significant in high-dose group at 
12 months follow-up
12 months [92]
de Windt 
et al. 
(2017)
10 Phase I/phase 
II single-center 
study
Modified 
Outerbridge 
grade 3 or 
grade 4
Allo BMMSCs +10 or 20% 
autologous chondrons
Nil Safety, KOOS, VAS, 
MRI, second-look 
arthroscopy, histology
No SUSAR; KOOS and VAS scores 
improved significantly; MRI, 
showed complete filling of the 
defect; arthroscopy, effective 
defect fill, and integration in the 
surrounding tissue; histology, 
positive staining for both type I and 
type II collagen and proteoglycan
12 months [93]
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Turajane 
et al. 
(2017)
60 RCT, single-
center study
KL grade 1 to 
grade 3
3 groups, 20 each; first 
group (AAPBSC + PRP 
+ G-CSF+ HA + MCS); 
second group (AAPBSC 
+ PRP + HA + MCS); third 
group (control) (all given 
weekly × 3 injections)
20 patients, IA, 
HA alone
Avoidance of TKA 
intervention and 
WOMAC scores
TKA done in three patients 
in the control group but not 
in the cell group; WOMAC, 
all groups reached statistically 
significant improvements 
within the individual (intra) 
groups
12 months [94]
Shapiro 
et al. 
(2017)
25 
patients, 
50 knees
RCT, 
single-blind, 
placebo-
controlled
Bilateral OA, 
KL grade 1 to 
grade 3
25 knees; 5 ml of  
Auto BMAC +10 ml 
of platelet-poor bone 
marrow plasma
25 knees; sterile 
saline, 15 ml
ICOAP, VAS scores, 
MRI, T2 mapping
No SAE, patients had a 
similar decrease in scores in 
VAS and ICOAP scores in 
both BMAC- and saline-
treated arthritic knees
6 months [95]
Park 
et al. 
(2017)
7 Open-label, 
single-arm, 
phase I/
phase II
KL grade 3 and 
ICRS grade 4
Two doses; Allo hUCB 
MSCs and HA hydrogel
Nil ICRS cartilage 
repair, VAS, IKDC, 
MRI, histological 
findings
VAS and IKDC improved at 
24 weeks and stable till 7 years; 
histology at 1 year showed 
hyaline-like cartilage; MRI at 
3 years showed the persistence 
of regenerated cartilage
7 years [96]
Nguyen 
et al. 
(2017)
30 Placebo-
controlled 
trial
KL grade 2 or 
grade 3
15 patients; AM + Auto 
AD (SVF + PRP; 107 SVF 
cells/ml)
15 patients, AM Safety, WOMAC, 
Lysholm, and 
modified VAS 
scores, MRI
Safety established, WOMAC 
scores not significant between 
two arms at 6 and 12 months 
but significant at 18 months; 
increased Lysholm and VAS 
scores in the treatment group 
compared with the placebo; 
MRI, MRI demonstrated 
cartilage layer was thicker in 
the treatment group
18 months [97]
Pintat 
et al. 
(2017)
19 Single-arm 
study
Patellofemoral 
OA
IA AD-MSC + PRP Nil WOMAC, MRI, T2 
mapping
WOMAC scores significantly 
lower in treatment arm than 
baseline; MRI, no change
12 months [98]
15 Th
e R
ole of M
esen
chym
a
l S
trom
a
l C
ells in
 th
e M
an
a
gem
en
t of O
steoarthritis of th
e K
n
ee
D
O
I: h
ttp
://d
x.d
oi.org/10.5772/in
tech
op
en
.86016
Author/
year
Sample 
size
Study design Grade of OA Cell type and dose Control group Outcome measures Outcomes Follow-up 
period
Reference
Russo 
et al. 
(2017)
30 Single-arm 
study
KL grade 1 
to grade 3, 
grade > II 
(ICRS 
classification)
Auto microfragmented 
adipose tissue
Nil VAS, KOOS, IKCD, 
subjective, Tegner 
Lysholm knee
IKDC and KOOS, 
improvement of 20 points; 
VAS and Tegner Lysholm 
score, improvement in 24 and 
31 points, respectively
12 months [99]
Yokota 
et al. 
(2017)
13 Single-arm 
study
KL grade 3 or 
grade 4
IA Auto AD- SVF; 2.5 ml 
SVF containing 3 × 107 
SVF cells/knee
Nil VAS, JKOM, 
WOMAC
Scores improved by an average 
of 35% over baseline for JKOM, 
32% improvement in WOMAC, 
and 40% for pain (VAS)
6 months [100]
Jo et al. 
(2017)
18 Single-arm 
study
Knee OA Auto AD-MSC; 3 doses 
(10 × 106, 50 × 106, and 
100 × 106 AD-MSCs)
Nil WOMAC, KSS, 
KOOS, VAS, MRI, 
size and depth of the 
cartilage defect, the 
signal intensity of 
regenerated cartilage 
and cartilage volume
No TEAE; WOMAC, KSS, 
and KOOS, improved knee 
function; VAS, improved pain 
(statistical significance in high 
dose); MRI, improvements in 
all parameters
24 months [101]
Garay 
Mendoza 
et al. 
(2017)
61 Open-label, 
phase I/phase 
II controlled 
trial
Knee OA Cell group, BM stimulation 
with subcutaneous 
administration of G-CSF 
(n = 30)
Control 
group, oral 
acetaminophen 
(n = 31)
VAS and WOMAC 
scores
BM-SC group showed 
significant improvement in 
knee pain and quality of life
6 months [102]
Kuah 
et al. 
(2018)
20 RCT, 
double-blind, 
placebo-
controlled
KL grade 1 to 
grade 3
Randomized 4:1; 
Progenza (PRG) (Allo 
AD-MSC + culture 
supernatant); 2 groups, 
8 pts. each, 3.9 or 6.7 
million cells
4 patients, 
placebo 
administered
Safety, WOMAC, 
VAS, AQoL-4D, 
biomarkers (urine, 
C2C and CTX-II; 
serum, MIF and 
CTX-I; MRI, 
MOAKS score)
All patients experienced at least 
one TEAE; VAS and WOMAC, 
statistically significant within-
group reduction from baseline 
in PRG group, no statistically 
significant differences at any 
time point between placebo and 
PRG groups; MRI, no decrease 
in lateral tibial cartilage 
volume while the placebo 
group showed a statistically 
significant cartilage loss
12 months [103]
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Matas 
et al. 
(2018)
29 Phase I/phase 
II RCT, triple-
blind trial
KL grade 1 to 
grade 3
Allo UC-MSC, single 
(20 × 106) or repeat dose 
(20 × 106 baseline and 
6 months), 10 pts. each
9 patients, HA 
(baseline and 
6 months)
VAS, WOMAC, 
MRI, WORMS score
No SAEs, repeat dose group 
had a significant decrease in 
VAS and WOMAC scores as 
compared to HA group, no 
changes in function subscale, 
SF36, and MRI
12 months [48]
Emadedin 
et al. 
(2018)
43 RCT, phase 
I/phase II, 
placebo-
controlled, 
triple-blind
KL grade 2 to 
grade 4
Auto BMMSC, 40 × 106 
cells (n = 19)
5 ml normal 
saline (placebo) 
(n = 24)
VAS, WOMAC, 
walking distance, 
painless walking 
distance, standing 
time and knee 
flexion compared
WOMAC, significant 
improvements in total score, 
pain, and physical function 
subscales and improvement 
in painless walking distance 
compared with placebo
6 months [104]
Khalifeh 
Soltani 
et al. 
(2019)
20 RCT, 
double-blind, 
placebo-
controlled
KL grade 2 to 
grade 4
Placental-derived MSC, 
50–60 x 106 cells (n = 10)
Normal saline 
(n = 10)
VAS, KOOS, knee 
flexion range of 
motion (ROM), 
MRI
No SAEs; significant knee ROM 
improvement at 2 and 24 weeks; 
VAS, no change; KOOS, 
improvement till 8 weeks; MRI, 
chondral thickness improved 
in about 10% of the total knee 
joint area AT 24 weeks
24 weeks [105]
AAPBSC, autologous activated peripheral blood stem cells; AD-MSCs, adipose tissue-derived mesenchymal stromal cells; AEs, adverse events; Auto, autologous; Allo, allogeneic; AM, arthroscopic microfracture; 
AQoL-4D, assessment of quality of life 4D questionnaire; BMAC, bone marrow aspirate concentrate; BMMSCs, bone marrow-derived mesenchymal stromal cells; C2C, type II collagen C2C peptide; CTX-1, 
C-terminal telopeptide of type I collagen; CTX-II, C-terminal telopeptide of type II collagen; dGEMRIC, delayed gadolinium-enhanced magnetic resonance imaging of cartilage; FRI, functional rating index; 
HA, hyaluronic acid; G-CSF, granulocyte colony-stimulating factor; IA, intra-articular; ICOAP, Intermittent and Constant Osteoarthritis Pain; ICRS, International Cartilage Repair Society Cartilage Injury 
Evaluation Package; IKDC, International Knee Documentation Committee Subjective Knee Evaluation Form; JKOM, Japanese Knee Osteoarthritis Measure; KL grade, Kellgren and Lawrence grade; KOOS, 
Knee Injury and Osteoarthritis Outcome Scores; KSS, Knee Society clinical rating system; MIF, macrophage migration inhibitory factor; MOAKS, MRI Osteoarthritis Knee Score; MOCART, magnetic resonance 
observation of cartilage repair tissue; MCS, mesenchymal cell stimulation; MRI, magnetic resonance imaging; NC, nucleated cells; PCI, poor cartilage index; PBPC, peripheral blood progenitor cells; PGA, 
patient global assessment; PR-FG, platelet-rich fibrin glue; PRP, platelet-rich plasma; QOL, quality of life; RCT, randomized controlled trial; RHSSK, Revised Hospital for Special Surgery knee scores; ROM, 
range of motion; SAE, serious adverse event; SAS, Short Arthritis Assessment Scale; SF-36, Short Form-36 quality of life questionnaire; SUSAR, suspected unexpected serious adverse reaction; SVF, stromal 
vascular fraction; TEAE, treatment emergent adverse event; TKA, total knee arthroplasty; TUG, timed up and go; UC-MSC, umbilical cord-derived MSC; VAS, visual analog pain score; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis Index; WORMS, whole-organ magnetic resonance imaging score.
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b. Best source of MSC for treatment of OA: Many studies have been published 
using different sources of MSCs, and there is no consensus as to which MSC 
type is the most effective in treating OA. Recently few studies have been pub-
lished using SVF, bone marrow aspirate concentrate, and micro-fragmented 
adipose tissue, which further adds to the variability of this issue. The most 
common problem affecting the clinical outcome in OA is the tendency of MSCs 
to differentiate into fibrous-like tissue instead of hyaline cartilage [108]. To 
eliminate or reduce chondrogenesis of the injected MSCs, one school of thought 
is to identify new sources of MSCs for cartilage repair. Recently synovium-
derived stem cells have been used for OA study as it is believed that epigenetic 
memory may play a role and impact the specific lineage differentiation of 
MSCs [109]. Hence, the use of synovium stem cells predicts a better outcome as 
chondrogenic differentiation is expected as it belongs to the same lineage. Fetal 
stem cells have higher plasticity and proliferation ability than adult stem cells. 
Hence, fetal tissue-derived stem cells, especially derived from the fetal cartilage, 
may show higher chondrogenic activity [110] and may be the ideal source of 
cells for OA. More controlled clinical trials are required to come to a conclusion 
as to which cell type may be the best choice for the effective treatment of OA.
c. Autologous or allogeneic source of MSCs: Most of the published trials used 
autologous MSCs to minimize immune response, which may lead to best clini-
cal outcomes. Six of the studies in Table 2 attempted to investigate the poten-
tial application of allogeneic MSCs [43, 48, 93, 96, 103, 105] in OA. Recently 
in the last 2–3 years, most of the studies have attempted to use an allogeneic 
source of MSCs due to the ease of application. Further, no observed serious 
adverse effects indicate the safety of allogeneic cells in OA. Around 3000 
patients have been administered allogeneic MSCs for different conditions, and 
no immune response has been reported to date [111]. In a recently published 
trial using allogeneic umbilical cord-derived MSCs (UC-MSC) in knee OA, 
patients were randomized to receive hyaluronic acid at baseline and 6 months 
(HA, n = 8), single-dose (20 × 106) UC-MSC at baseline (MSC-1, n = 9), or 
repeated UC-MSC doses at baseline and 6 months (20 × 106 × 2; MSC-2, n = 9). 
No serious adverse events were reported. At 12 months of follow-up, MSC-2-
treated group had significantly lower levels of pain [visual analog score (VAS), 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 
total score, and pain subscale] than HA group [48]. Hence, it can be safely 
concluded that the use of allogeneic MSCs is safe and may be efficacious in OA.
d. The optimal dose of MSCs for best efficacy in OA: MSCs have been used in 
different doses in several clinical trials of OA (Table 2). The dose varied from as 
low as 1.18 million cells [79] to as high as 150 million cells [43]. In a study by Koh 
et al. [79], 18 patients were given intra-articular injections with adipose tissue-
derived MSCs in a mean dose of 1.18 million cells and platelet-rich plasma. At 
26 months of follow-up, patients had significant improvement in VAS, Lysholm, 
and WOMAC scores. Magnetic resonance imaging (MRI) was evaluated using 
WORMS score and showed statistically significant improvement in the total 
and cartilage scores. In another dose-finding study, Pers et al. [90] recruited 18 
patients who were treated with autologous AD-MSCs in three different doses: low 
dose (2 × 106 cells), medium dose (10 × 106 cells), and high dose (50 × 106 cells). 
After 6 months of follow-up, the procedure was found to be safe, and no serious 
adverse events were reported. Patients in the low dose had significant improve-
ment in pain levels and functions as compared to baseline. In a dose-finding study 
conducted by Gupta et al. [43], four different doses (25, 50, 75 and 150 million 
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cells) of allogeneic BMMSCs were used in a total of 60 patients. At 1 year of 
follow-up, the lower doses of 25 million had shown improvement in pain levels 
and function as compared to placebo and baseline. However in a study by Jo 
et al. [101], 18 patients were injected with autologous AD-MSCs in three dif-
ferent doses: 10, 50, and 100 million cells. At 2 years of follow-up, significant 
improvement in the Knee Society clinical rating system (KSS), Knee Injury and 
Osteoarthritis Outcome Score (KOOS), and VAS scores was seen in the highest 
dose of 100 million cells. As can be seen, most of the studies are single-arm studies 
without any control arm. Hence, to determine the most efficacious dose in OA, 
more randomized controlled, dose-finding clinical trials are required.
e. Selection of endpoints for the conduct of clinical trial: The FDA 2018 draft 
guidance document for OA regarding the development of structural endpoints for 
the development of drugs, devices, and biological products for treatment states 
that approvals for OA to date have been based on patient-reported outcome meas-
ures that assess pain and function. For the development of new product in OA, 
the goal of treatment should be inhibition of structural damage or targeting the 
underlying pathophysiology associated with OA or significantly delay the com-
plications of joint failure and the need for joint replacement and also to reduce the 
deterioration of function and worsening of pain. All of the above may be taken 
into consideration for the development of endpoints for the study in OA [112].
Recently a meta-analysis was done to evaluate the different endpoints used 
to see the therapeutic efficacy and safety of MSCs for the treatment of patients 
with knee osteoarthritis [113]. Five hundred eighty-two patients in 11 random-
ized controlled trials were included in this meta-analysis. It showed that MSC 
treatment significantly improved VAS and International Knee Documentation 
Committee (IKDC) scores after 24 months of follow-up compared to controls. 
MSC therapy also showed significant improvement in the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC), Lequesne algofunctional 
indices (Lequesne), Lysholm knee scale (Lysholm), and Tegner activity scale 
(Tegner) at 12 or 24 months of follow-up. Hence, all the endpoints used currently 
for evaluation of efficacy in OA have shown significant improvement in different 
clinical trials:
f. MRI to evaluate cartilage regeneration: MRI has emerged as the leading 
method of imaging soft tissue structures around joints. An ideal MRI study 
for the cartilage should provide an accurate assessment of cartilage thickness 
and volume, show morphologic changes of the cartilage surface, show internal 
cartilage signal changes, and allow evaluation of the subchondral bone for signal 
abnormalities. Also, it would be desirable for MRI to provide an evaluation of the 
underlying cartilage physiology, including providing information about the sta-
tus of the glycosaminoglycan (GAG) and collagen matrices [114]. But, in actual, 
there is an absence of a standard system by MRI to evaluate cartilage regenera-
tion. Many studies as given in Table 2 that have used MRI to evaluate cartilage 
regeneration are only qualitative. It is recommended to use validated imaging 
outcomes for cartilage regeneration for scientifically validating cell-based thera-
pies, thus advancing the field. The most common parameters used for evaluation 
of cartilage regeneration by MRI are cartilage thickness in different points in all 
the compartments of the joint [97], cartilage volume [101], whole-organ magnetic 
resonance imaging score (WORMS) [43, 48], T2 relaxation time mapping [78, 83, 
85, 95, 98], MRI Osteoarthritis Knee Score (MOAKS) score [88, 103], magnetic 
resonance observation of cartilage repair tissue (MOCART) score [88],  
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and contrast-enhanced imaging technique known as delayed gadolinium-
enhanced MRI of cartilage (dGEMRIC) [90]. Among all the parameters, T2 
mapping and WORMS seem to be the most commonly used qualitative parame-
ters used for evaluation of cartilage regeneration as it is sensitive to both changes 
in cartilage hydration and collagen fibril orientation. In a study by Orozco et al. 
[78], T2 relaxation measurements demonstrated a highly significant decrease of 
poor cartilage areas (on average, 27%), with the improvement of cartilage quality 
in 11 of the 12 patients. In another study by Rich et al. [83], a total of 50 patients 
was evaluated by T2 mapping at 12 months of follow-up after administration 
of autologous BMMSCs. The mean poor cartilage index (PCI) significantly 
decreased in 37 of 50 patients (74%), 10 remained the same (20%), and 3 wors-
ened between 7 and 10% (6%). Hence, cartilage T2 mapping may be a sensitive 
marker for monitoring cartilage quality in subjects with knee OA as it allows us to 
accurately determine the grade of disorganization of the extracellular matrix.
g. Use of MSC alone or MSC with a scaffold for intra-articular injection in OA: 
When MSCs are injected intra-articularly alone, MSCs scatter widely in the 
joint, making it impossible to obtain consistent local concentration at the site of 
cartilage defect. Hence, with a hope to enhance their efficacy in cartilage regen-
eration, MSC implantation using scaffolds is being attempted in different clini-
cal trials so that the cells are delivered to the site of interest. Compared to direct 
intra-articular injection, MSC delivery via a scaffold affords more control of 
proliferation, matrix production, and self-renewal which may help in the regen-
eration/repair of degenerated or damaged articular cartilage. Different scaffolds 
have been designed as the delivery system for the repair of articular cartilage. 
The different scaffolds which can be used are either made of poly-lactic-co-
glycolic acids (PLGA) [115], collagen [116], gelatin [117], tricalcium (TCP) 
[118], poly-lactic acid (PLA) [115], hyaluronic acid (HA) [119], poly-glycolic 
acid (PGA), or fibrin glue [120]. HA has been used frequently for implantation 
of MSCs into the joint. Many clinical studies (Table 2) have used HA as scaffold 
along with MSCs for implantation of the cells. Cartistem®, an approved drug 
by the Korean FDA for knee OA, is a combination of human umbilical cord 
blood-derived MSCs and sodium hyaluronate which is directly implanted at 
the site of cartilage injury into the joint by arthroscopy [96, 121]. Hence, cells 
with scaffold are the ideal combination for intra-articular delivery for cartilage 
degeneration. However, further studies are necessary to find optimal implanta-
tion vehicles that can result in the regeneration of articular cartilage.
8.3 Clinical trials in India
Few clinical trials using autologous or allogeneic MSCs or mononuclear stem 
cells in OA have been conducted in India. The trials registered in the Clinical Trials 
Registry of India are the two trials done by Stempeutics (one phase II trial com-
pleted and the other phase III trial ongoing). However, one published trial by Bansal 
et al. [122] for the single-arm study was done in India in which a total of 10 patients 
were treated with AD-MSCs. The patients were evaluated for safety, WOMAC, 
6-minute walk test (6MWT), and MRI for cartilage thickness. The patients were 
followed up for 2 years. The total WOMAC and its subscale scores and 6MWT 
were significantly improved at all-time points till 2 years of follow-up. Cartilage 
thickness as determined by MRI improved by at least 0.2 mm in six patients, was 
unchanged in two patients, and decreased by at least 0.2 mm in two patients. The 
authors concluded that the procedure demonstrated a strong safety profile with no 
severe adverse events or complications reported.
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8.4 Stempeutics Research experience in osteoarthritis of the knee joint
The off-the-shelf allogeneic, pooled BMMSC product developed by Stempeutics 
has completed one phase II clinical trial [43] and currently ongoing phase III trial 
in knee OA. In our completed phase II trial, we included patients of idiopathic OA 
in grade 2 or 3 of Kellgren and Lawrence radiographic criteria; patients who had 
self-reported difficulty in at least one of the following activities attributed to knee 
pain, lifting and carrying groceries, walking 400 m, getting in and out of a chair, or 
going up and down stairs; and patients who had been on stable medication, includ-
ing nonsteroidal anti-inflammatory drugs/opioid analgesics for the past 3 months 
and in the age group of 40–70 years. All the criteria have to be present before being 
included in the study [43].
8.4.1 Phase II study in patients with osteoarthritis of the knee joint
The phase II results of Stempeucel® in OA patients have been published [43]. 
Briefly, it was a double-blind, randomized, placebo-controlled, dose-finding study. In 
this study, 60 OA patients were randomized to receive different doses of Stempeucel®, 
25, 50, 75, and 150 million cells or placebo. Stempeucel® was administered intra-artic-
ularly (IA) to the knee joint followed by 2 ml of hyaluronic acid (20 mg). The subjects 
were followed up for 2 years and were evaluated for safety parameters including AEs, 
and for efficacy parameters, VAS for pain, Intermittent and Constant Osteoarthritis 
Pain (ICOAP), WOMAC (total score and its subscales), and MRI were done to evaluate 
the WORMS score. The intra-articular administration of Stempeucel® was safe with 
knee pain and swelling as the most common AEs. Clinically relevant improvement in a 
persistent manner was seen in 25 million dose group in all subjective parameters (VAS, 
ICOAP, and WOMAC scores) (Figures 2–4). WORMS of MRI knee did not reveal any 
difference from the baseline and placebo group. It was concluded that intra-articular 
administration of Stempeucel® is safe and 25 million dose may be the most effective 
among the doses tested.
Currently, we are conducting a phase III trial in OA of the knee joint. This is a 
randomized, double-blind, multicentric, placebo-controlled study assessing the 
efficacy and safety of intra-articular administration of Stempeucel® in patients 
with osteoarthritis of the knee joint. One hundred and forty-six patients will be 
Figure 2. 
Visual analog scale values. Data presented as mean value ± SD; C1 = cohort 1; C2 = cohort 2; 25M, 50M, 75M, 
150M = 25, 50, 75, 150 million cells, respectively; 1M, 3M, 6M, 12M = 1, 3, 6, 12 months, respectively.
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randomized to stem cell and placebo arm in a ratio of 1:1. Seventy-three patients 
will receive Stempeucel® (25 million) followed by 2 ml of hyaluronan, and 73 
patients will receive only intra-articular injection of 2 ml of placebo followed by 
2 ml of hyaluronan. The patients will be followed up for a total of 2 years after IMP 
administration. The details of the study are found in the Clinical Trials Registry of 
India (CTRI/2018/09/015785).
Figure 3. 
WOMAC results. WOMAC: (A, B) composite; (C, D) pain; (E, F) stiffness; and (G, H) physical function. 
Data presented as mean value ± SD; C1 = cohort 1; C2 = cohort 2; 25M, 50M, 75M, 150M = 25, 50, 75, 150 
million cells, respectively; 1M, 3M, 6M, 12M = 1, 3, 6, 12 months, respectively; WOMAC = Western Ontario 
and McMaster Universities Osteoarthritis Index.
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9. Conclusion
Osteoarthritis is a common disorder involving damage to synovial joint tis-
sues particularly the cartilage and bone. Current treatments are mostly targeted 
at end-stage disease, but biological therapies including stem cell therapy show a 
promise for earlier intervention with a more prolonged benefit. With all the pub-
lished clinical trial data, it is reasonable to expect that MSCs may prove to be an 
important therapy for OA. Pooled BMMSCs with their enhanced anti-inflammatory 
potential, immunomodulatory properties, and secretion of paracrine factors create 
the optimum environment for a controlled reparative pathway in the affected joint. 
Pooled BMMSC treatment, perhaps combined with other modalities like a scaffold, 
would be advantageous in providing treatment in early OA to slow disease progres-
sion, thus delaying or avoiding total joint replacement.
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